N-isoamyl-N-(6-ethylnaphthalene-2-sulfonyl)-D-valine hydroxamic acid | 1205122-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-isoamyl-N-(6-ethylnaphthalene-2-sulfonyl)-D-valine hydroxamic acid
• 英文别名: (2R)-2-[(6-ethylnaphthalen-2-yl)sulfonyl-(3-methylbutyl)amino]-N-hydroxy-3-methylbutanamide
• CAS: 1205122-57-1
• 化学式: C₂₂H₃₂N₂O₄S
• 分子量: 420.573
• InChiKey: UXOSVQFKXFZCKF-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP-12 ET MMP-13 À BASE D'ACIDE HYDROXAMIQUE
  申请人：NOVARTIS AG

  公开号：WO2010007027A1

  公开（公告）日：2010-01-21

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种具有化学式(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-12和/或MMP-13异常活性特征的疾病或疾病。因此，化合物的化学式(I)可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括化学式(I)的化合物的药物组合物。
• SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
  申请人：McQuire Leslie Wighton

  公开号：US20110112076A1

  公开（公告）日：2011-05-12

  The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).

  本发明提供了一种式子为(I)的化合物，该化合物是MMP-12和/或MMP-13的抑制剂，因此可用于治疗MMP-12和/或MMP-13活性异常引起的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了包括式(I)的化合物的药物组合物。
• US8841291B2
  申请人：——

  公开号：US8841291B2

  公开（公告）日：2014-09-23